

NOTICE OF PRICE ADJUSTMENT TO PHS COVERED ENTITIES

As part of its ongoing compliance efforts, Teva Pharmaceuticals, Inc. ("Teva") is adjusting certain prices charged for products it acquired bearing labeler codes 00228, 00472, 00591, 14550, 16252, 45963, 52152, 52544, 62037, and 67767 for the period from the first quarter of 2014 through the third quarter of 2017. The need for the adjustments stems from Teva's recalculation of average manufacturer prices and best prices reported to CMS under the Medicaid Drug Rebate Program for the period relevant to the restatement. Teva will offer to refund each PHS Covered Entity the amount of all identified overcharges. The refunds will not be reduced by the amount that any Covered Entity was inadvertently undercharged.

Teva has identified the Covered Entities that were overcharged and will contact them by U.S. mail during Q3 2020 and distribute refunds as follows:

- **Covered Entities Due Refunds in Excess of \$50.00:** In an initial mailing, Teva will notify those Covered Entities that were overcharged by more than \$50.00 about the refund and it will issue the refund check to the Covered Entity in the appropriate amount.
- **Covered Entities Due Refunds of \$50.00 or Less:** The initial mailing to Covered Entities with incurred overcharges of \$50.00 or less will ask to provide additional direction as to whether or not they request a check for the full amount of the identified overcharges.
- Teva also will issue refunds to any Covered Entity that is not contacted initially by Teva, provided the Covered Entity can document that it purchased a Teva product subject to an overcharge during the relevant period and that it was a qualified Covered Entity enrolled in the 340B Program at the time of the purchase.

Covered Entities that wish to inquire about this refund program should contact:

Teva Membership, 400 Interpace Parkway, Parsippany NJ 07054 or
Teva.340BInquiry@tevapharm.com.